公开(公告)号：US20180110779A1

公开(公告)日：2018-04-26

申请号：US15849770

申请日：2017-12-21

Applicant: Novartis AG

Inventor： Stephane FERRETTI ,  Sebastien JEAY

IPC: A61K31/506 ,  A61K45/06 ,  A61K9/00

CPC classification number: A61K31/506 ,  A61K9/0019 ,  A61K31/402 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/472 ,  A61K31/496 ,  A61K45/06

Abstract: The present disclosure relates to mdm2 inhibitors for use in specific dosing schedules. It was found that if sufficiently potent or, in alternative, sufficiently high dose of a Mdm2 inhibitor is used, it can cause antineoplastic effect by triggering much longer lasting antiproliferative mechanism in cells. The long lasting effect can sustain for several weeks after a single dose, which eliminates the need for daily treatment and allows administering the Mdm2i intermittently. A treatment with the intermittent dosing schedule of a Mdm2 inhibitor can be combined with a daily treatment of the Mdm2i or with another pharmaceutically acceptable ingredient.